Triangle startups continue to raise new money with three firms combining for nearly $3 million, according to securities filings.

  • Youth Digital

Chapel Hill-based Youth Digital raised the largest amount at $1,999,999, according to a filing made with the Securities and Exchange Commission on Monday.

Target and Best Buy recently began offering Youth Digital products.

“Kids Ages 8-14 Learn to Code, Design, Develop, and Create with Technology,” the company says.

  • iScribes

Durham-based iScribes has raised $325,000 with a target of $500,000. According to the SEC filing, the funding is debt.

iScribes, which describes itself as a “virtual scribing service” for phyisians, raised $360,000 in equity in December 2014.

The company touts its offering this way:

“Our HIPAA compliant technology solution seamlessly integrates a remote scribe into the physician’s workflow.

“A physician with iScribes technology treats a patient, and the encounter is streamed to a secure server.

“A highly trained medical scribe accesses the encounter and completes the documentation directly in the provider’s electronic medical record.

“The physician reviews and approves the documentation at his convenience.”

  • KinoDyn

Also raising capital is biotech startup KinoDyn. The Chapel Hill-based firm has closed on just under $350,000, which was its target.

Two investors participated in the round.

KinoDyn is a cancer drug discovery company that is developing “a proprietary technology using multiplexed inhibitor beads and mass spectroscopy (MIB/MS). The technology simultaneously maps and quantifies important cellular enzymes, kinases, and determines their kinome-wide response to targeted therapeutics. The MIB/MS technology is sensitive and robust enough to use on human cancer patient samples and provides a ‘first-of-its-kind’ approach to discover new drugs or drug combinations for cancer therapy. We are currently focused on challenging cancers including triple negative breast cancer (TNBC), pancreatic cancer, drug-resistant leukemias and glioblastoma.”